Project Immune-Image: Specific Imaging of Immune Cell Dynamics Using Novel Tracer Strategies

Basic data

Title:
Immune-Image: Specific Imaging of Immune Cell Dynamics Using Novel Tracer Strategies
Duration:
01/10/2019 to 30/09/2024
Abstract / short description:
Immunotherapies have emerged as effective treatments for immune system-related diseases, such as cancer and
inflammatory diseases. Although immunotherapeutics are effective not all patients benefit and side effects vary greatly.
Thus, there is an unmet need for a personalized approach. Blood and tissue biomarkers have played only a modest role up
until now in assessing immune status in vivo and we believe that non-invasive whole body imaging will make a significant
contribution in the future. Although the field of imaging (PET, MRI, Optical Imaging) is flourishing, its application to patient
immune status measurement and monitoring has barely been explored. Within Immune-Image we aim to develop new
immunotracers for imaging specific immune cell subsets, develop quantitative imaging workflows, validate the
immunotracers pre-clinically in relevant disease models, produce the tracers in a Good Manufacturing Practice (GMP)-
compliant way, and conduct smart clinical trials, including with novel tracers.
To this end, insights will be gained into the optimal use of drugs and a more efficient development of immunotherapeutics.
Moreover, the success rate of immunotherapy development will be enhanced since our molecular imaging platform will
provide novel insights into patient immune status, which will support drug development and treatment decisions.
To achieve our goals, we have assembled an experienced international multi-disciplinary consortium composed of chemists,
biologists, immunologists, physicists, pharmacists, information technologists, and medical specialists with diverse and
essential backgrounds who will join forces to design, synthesise, evaluate and validate immunotracers and create
sustainable molecular imaging techniques that can be broadly applied in the assessment of the immune status and immune
modulation of patients. There will be input from patients and regulators in order to assure optimal design and execution of
immunotracer clinical trials.

Involved staff

Managers

Faculty of Medicine
University of Tübingen
Department of Dermatology
Hospitals and clinical institutes, Faculty of Medicine

Contact persons

Faculty of Medicine
University of Tübingen

Other staff

Faculty of Medicine
University of Tübingen
Faculty of Medicine
University of Tübingen
Faculty of Medicine
University of Tübingen
Faculty of Medicine
University of Tübingen

Local organizational units

Department of Preclinical Imaging and Radiopharmacy
Department of Radiology
Hospitals and clinical institutes, Faculty of Medicine
Department of Nuclear Medicine and Clinical Molecular Imaging
Department of Radiology
Hospitals and clinical institutes, Faculty of Medicine
Department of Dermatology
Hospitals and clinical institutes
Faculty of Medicine
Department VIII, Medical Oncology and Pulmonology
Department of Internal Medicine
Hospitals and clinical institutes, Faculty of Medicine

Funders

Brüssel, Belgium
Help

will be deleted permanently. This cannot be undone.